Cardio-focused digital health company AliveCor landed FDA clearance for its new suite of interpretive ECG algorithms, dubbed the Kardia AI V2. This news comes just days after the company announced a $65 million Series E funding round.
The new clearance will is able to capture sinus rhythm with premature ventricular contractions, sinus rhythm with supraventricular ectopy and a sinus rhythm with...
New data from an international study of AliveCor’s smartphone app and accompanying two-wire ECG found the mobile tool to be on par with a standard 12-lead ECG among patients presenting with ST-segment elevation myocardial infarction (STEMI).
In the study — which was conducted in conjunction with AliveCor and presented this weekend at the American Heart Association’s 2018 Scientific Session in...
Apple may be moving towards commoditizing the on-the-wrist ECG, but other companies in the space aren’t resting on their laurels. AliveCor, which has offered an smartphone-connected ECG since 2012 and a wristworn version since 2016, revealed today the company’s next direction: a six-lead ECG compatible with a smartphone.
“For the last year our challenge has not … been in making our devices...
Over the weekend AliveCor announced that its technology was validated in two studies. The first found that its KardiaBand, which works as a personal electrocardiogram device, can accurately detect atrial fibrillation (AFib) when used with the Apple Watch. The second study, which was a collaboration with the Mayo Clinic found that its ECG device, when paired with AI, could detect hyperkalemia.
“...
A new study from the University of Buffalo showed that not only did AliveCor's smartphone-connected heart monitor detect as many arrythmias as a traditional 14-day cardiac event monitor, but patients were also considerably more adherent to the smartphone-connected device.
"The point of the study was to determine whether any smartphone app could be good enough to replace what we normally use now,...
The results are in for the Scripps Translational Science Institute’s Wired For Health study, and there’s no sugar-coating it: they’re disappointing for those working in digital health. The six-month randomized control trial found no short-term benefit in health costs or outcomes for patients monitoring their health with connected devices.
“It was a bit disappointing, but remember, this was the...
Utah health system Intermountain Healthcare -- and other, as yet unknown providers -- appear to be investigating AliveCor's smartphone ECG device in a clinical context, to determine whether the iPhone version of the device is comparable with traditional 12-lead ECGs. The trial aims to test the device with 50 patients who have possible ST Elevation Myocardial Infarction (STEMI), a common type of...
AliveCor launched its new third generation smartphone-connected EKG device, a model that is both slimmed down and considerably cheaper than its predecessors. The device will sell for $74.99, compared to the previous model's $199 price tag, and is 50 percent thinner and 40 percent lighter.
"The new AliveCor third generation device is a lower-profile consumer design," Cindy Donohoe, vice president...
Japan-based medical device company Omron Healthcare has partnered with AliveCor to help bring AliveCor's FDA-cleared smartphone-connected electrocardiogram (ECG) to more online and brick and mortar retailers.
AliveCor CEO Euan Thomson told MobiHealthNews in an interview that Omron already sells its own products at various retailers, and through this partnership, Omron will bring AliveCor's...
Smartphone-enabled ECG medical device maker AliveCor and Greatcall, which makes a line of mobile phones and health services marketed to seniors, have partnered to bring the AliveCor device to GreatCall phones.
“Heart disease is the leading cause of death in the US, claiming about 1 million lives each year,” David Inns, CEO of GreatCall, said in a statement. “With access to an easy-to-use,...
